Comparable Outcomes of Differentiated Thyroid Cancer in Immunocompromised Versus Immunocompetent Patients
Authors' conclusion
DTC has a comparable prognosis in immunocompetent and immunocompromised patients.
Study context
- Population
- Adults with differentiated thyroid cancer (DTC) treated at Memorial Sloan-Kettering Cancer Center, 1987–2020DTC patients screened
- Participants
- 8,534 adults
- Exposure
- Immunocompromised vs propensity-matched immunocompetent patients with DTC
- Immunocompromisedn = 130
- Immunocompetentn = 650reference
- Outcome
- Recurrence-free survival
- Follow-up
- 180 months
Methodological detailspropensity-score matched, 5:1 comparison ratio, single-centre
- Propensity-score matched
- 5:1 comparison ratio
- Single-centre
Main finding
As reported in the abstract
- Recurrence rates below 10% in both cohorts over 180 months
- Immunocompromised vs Immunocompetent: P = 0.94
- Propensity-matched cohort
Observational data: associations, not effects.
Further findings
Disease-specific survival · 10 years · similar
P = 0.34
Original publication
Comparable Outcomes of Differentiated Thyroid Cancer in Immunocompromised Versus Immunocompetent Patients. J Clin Endocrinol Metab. Published 7 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →